Filtered By:
Specialty: Drugs & Pharmacology
Cancer: Brain Cancers
This page shows you your search results in order of date.
Order by Relevance | Date
Total 150 results found since Jan 2013.
Development of microRNA-based therapeutics for central nervous system diseases
Eur J Pharmacol. 2023 Aug 2:175956. doi: 10.1016/j.ejphar.2023.175956. Online ahead of print.ABSTRACTMicroRNA (miRNA)-mediated gene silencing is a method of RNA interference in which a miRNA binds to messenger RNA sequences and regulates target gene expression. MiRNA-based therapeutics have shown promise in treating a variety of central nervous system diseases, as verified by results from diverse preclinical model organisms. Over the last decade, several miRNA-based therapeutics have entered clinical trials for various kinds of diseases, such as tumors, infections, and inherited diseases. However, such clinical trials for ...
Source: European Journal of Pharmacology - August 4, 2023 Category: Drugs & Pharmacology Authors: Siqi Xia Chaoran Xu Fuyi Liu Gao Chen Source Type: research
Neuroprotective Strategies for Stroke by Natural Products: Advances and Perspectives
Curr Neuropharmacol. 2023 Jul 17. doi: 10.2174/1570159X21666230717144752. Online ahead of print.ABSTRACTCerebral ischemic stroke is a disease with high prevalence and incidence. Its management focuses on rapid reperfusion with intravenous thrombolysis and endovascular thrombectomy. Both therapeutic strategies reduce disability, but the therapy time window is short, and the risk of bleeding is high. Natural products (NPs) have played a key role in drug discovery, especially for cancer and infectious diseases. However, they have made little progress in clinical translation and pose challenges to the treatment of stroke. Rece...
Source: Current Neuropharmacology - July 17, 2023 Category: Drugs & Pharmacology Authors: Aifen Liu Jingyan Hu Tzu-Shao Yeh Chengniu Wang Jilong Tang Xiaohong Huang Bin Chen Liexiang Huangfu Weili Yu Lei Zhang Source Type: research
Rev-erb α agonist SR9009 protects against cerebral ischemic injury through mechanisms involving Nrf2 pathway
Conclusion: Taken together, Rev-erbα activation by SR9009 protects against ischemic stroke damage, at least, partly through Nrf2 pathway.PMID:37063298 | PMC:PMC10102520 | DOI:10.3389/fphar.2023.1102567
Source: Pharmacological Reviews - April 17, 2023 Category: Drugs & Pharmacology Authors: Mingyue Sheng Xun Chen Yan Yu Qi Wu Junping Kou Gangling Chen Source Type: research
New paradigms in purinergic receptor ligand discovery
Neuropharmacology. 2023 Mar 13:109503. doi: 10.1016/j.neuropharm.2023.109503. Online ahead of print.ABSTRACTThe discovery and clinical implementation of modulators of adenosine, P2Y and P2X receptors have progressed dramatically in ∼50 years since Burnstock's definition of purinergic signaling. Although most clinical trials of selective ligands (agonists and antagonists) of these nineteen receptors failed, there is a renewed impetus to redirect efforts to new disease conditions and the discovery of more selective or targeted compounds with potentially reduced side effects, such as biased GPCR agonists. The elucidation of...
Source: Neuropharmacology - March 15, 2023 Category: Drugs & Pharmacology Authors: Kenneth A Jacobson Balaram Pradhan Zhiwei Wen Asmita Pramanik Source Type: research
DL-3-n-butylphthalide (NBP) alleviates poststroke cognitive impairment (PSCI) by suppressing neuroinflammation and oxidative stress
In this study, we aimed to investigate the influences of NBP on cognitive function in an ischemic reperfusion (I/R) rat model. Our results showed that NBP profoundly decreased neurological scores, reduced cerebral infarct areas and enhanced cerebral blood flow (CBF). NBP potently alleviated poststroke cognitive impairment (PSCI) including depression-like behavior and learning, memory and social cognition impairments, in I/R rats. NBP distinctly suppressed the activation of microglia and astrocytes and improved neuron viability in the ischemic brain. NBP inhibited the expression of inflammatory cytokines, including interleu...
Source: Frontiers in Pharmacology - January 11, 2023 Category: Drugs & Pharmacology Source Type: research
Exploring the potential mechanism of Fritiliariae Irrhosae Bulbus on ischemic stroke based on network pharmacology and experimental validation
Conclusion: Based on network pharmacology, the effect of FIB in the treatment of ischemic strokes was discussed through the multi-component-multi-target-multi-pathway. The therapeutic effect and potential mechanisms of FIB on ischemic strokes were preliminarily explored, which provided a ground work for further researches on the pharmacodynamic material basis, mechanism of action and clinical application.
Source: Frontiers in Pharmacology - November 17, 2022 Category: Drugs & Pharmacology Source Type: research
Synthesis and Pharmacological Evaluation of Novel Triazole-Pyrimidine Hybrids as Potential Neuroprotective and Anti-neuroinflammatory Agents
ConclusionThe possible mechanism of action was observed through the inhibition of ER stress, apoptosis, and the NF-kB inflammatory pathway. Thus, our study strongly indicates that the novel scaffolds of triazole-pyrimidine-based compounds can potentially be developed as neuroprotective and anti-neuroinflammatory agents.Graphical Abstract
Source: Pharmaceutical Research - November 14, 2022 Category: Drugs & Pharmacology Source Type: research
From kitchen to clinic: Pharmacotherapeutic potential of common spices in Indian cooking in age-related neurological disorders
Aging is described as an advanced time-related collection of changes that may negatively affect with the risk of several diseases or death. Aging is a main factor of several age-related neurological disorders, including neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, and dementia), stroke, neuroinflammation, neurotoxicity, brain tumors, oxidative stress, and reactive oxygen species (ROS). Currently available medications for age-related neurological disorders may lead to several side effects, such as headache, diarrhea, nausea, gastrointestinal (GI) diseases, dyskinesia, and hallucinosis. These day...
Source: Frontiers in Pharmacology - November 10, 2022 Category: Drugs & Pharmacology Source Type: research
Podoplanin: Its roles and functions in neurological diseases and brain cancers
Podoplanin is a small mucin-like glycoprotein involved in several physiological and pathological processes in the brain including development, angiogenesis, tumors, ischemic stroke and other neurological disorders. Podoplanin expression is upregulated in different cell types including choroid plexus epithelial cells, glial cells, as well as periphery infiltrated immune cells during brain development and neurological disorders. As a transmembrane protein, podoplanin interacts with other molecules in the same or neighboring cells. In the past, a lot of studies reported a pleiotropic role of podoplanin in the modulation of th...
Source: Frontiers in Pharmacology - September 13, 2022 Category: Drugs & Pharmacology Source Type: research
Nose to brain delivery of melatonin lipidic nanocapsules as a promising post-ischemic neuroprotective therapeutic modality
Drug Deliv. 2022 Dec;29(1):2469-2480. doi: 10.1080/10717544.2022.2104405.ABSTRACTIschemic stroke accounts for about 87% of all strokes, causing long-term disability in adults, and is the second leading cause of death worldwide. In search of new therapeutic modalities, the use of neuroprotective agents loaded in nanocarriers to be delivered by noninvasive means (i.e. via intranasal route) became a popular approach. In the current study, melatonin (MEL) was loaded in lipidic nanocapsules (LNCs) prepared using the phase inversion method, and characterized in terms of size, polydispersity, zeta potential, in vitro drug release...
Source: Drug Delivery - July 27, 2022 Category: Drugs & Pharmacology Authors: Eman A Bseiso Sarah A AbdEl-Aal Maha Nasr Omaima A Sammour Nabaweya A Abd El Gawad Source Type: research
